Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZG2 | ISIN: US14216R1014 | Ticker-Symbol: W2J
Tradegate
15.05.25 | 15:14
0,180 Euro
+4,71 % +0,008
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CARISMA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CARISMA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1560,17416:19
0,1600,16916:19

Aktuelle News zur CARISMA THERAPEUTICS INC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CARISMA THERAPEUTICS INC Aktie jetzt für 0€ handeln
DiCarisma Therapeutics Inc. - 10-Q, Quarterly Report4
29.04.Carisma Therapeutics Inc. - 10-K/A, Annual Report1
16.04.Carisma Therapeutics Inc. - 8-K, Current Report1
01.04.Carisma winds down operations, lays off 95% of remaining staff14
31.03.Carisma Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans4
10.01.Carisma Therapeutics Inc. - 8-K, Current Report11
26.12.24Carisma Therapeutics Inc. - 8-K, Current Report8
16.12.24Carisma downgraded by H.C. Wainwright to neutral8
12.12.24Carisma downgraded by Baird over lack of near-term catalysts12
09.12.24Carisma axes sole clinical cell therapy candidate, lays off 23 workers5
09.12.24Carisma Therapeutics Reprioritizes Pipeline, Cuts Jobs8
09.12.24Carisma Therapeutics Announces Strategic Reprioritization Of Pipeline; To Cut Workforce By 34%4
09.12.24Carisma Therapeutics shifts focus, cuts workforce by 34%2
09.12.24Carisma Therapeutics ändert Fokus und reduziert Belegschaft um 34%19
09.12.24Carisma Therapeutics Inc.: Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline149Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525...
► Artikel lesen
09.12.24Carisma Therapeutics Inc. - 8-K, Current Report-
17.11.24Carisma Reports Promising Preclinical Data On Engineered Macrophages For Liver Fibrosis5
08.11.24Carisma Therapeutics Inc.: Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma164New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA, Nov....
► Artikel lesen
07.11.24Carisma Therapeutics Inc.: Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights134Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for liver...
► Artikel lesen
10.09.24Carisma, Moderna To Expand Collaboration; Moderna Nominates Two Autoimmune Disease Targets471WASHINGTON (dpa-AFX) - Carisma Therapeutics (CARM) announced the expansion of in vivo chimeric antigen receptor macrophage and monocyte collaboration with Moderna, Inc. (MRNA) to include the...
► Artikel lesen
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2